" class="no-js "lang="en-US"> Habib Nehme - Medtech Alert
Sunday, January 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Habib Nehme

Habib Nehme

About Habib Nehme

Experienced Executive Vice President with a demonstrated history of working in the medical device industry. Skilled in Analytical Skills, Sales, Management, Biomedical Engineering, and Leadership. Strong business development professional graduated from HEC Paris.

Related Story

News

 More Cancer Patients in Africa to Benefit from Advanced Radiation Therapy with Elekta Unity MR-Linac | Pharmtech Focus

More Cancer Patients in Africa to Benefit from Advanced Radiation Therapy with Elekta Unity MR-Linac

November 25 2021

Elekta (EKTA-B.ST) announced today that its latest African order for Elekta Unity MR-Linac comes less […]